about
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cellsBcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viabilityA tissue-restricted cAMP transcriptional response: SOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytesTranscriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanomaIntegrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanomaMolecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.An oncogenic role for ETV1 in melanoma.CXCR4 pathway associated with family history of melanoma.Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.Imatinib targeting of KIT-mutant oncoprotein in melanoma.A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression.RSK activation of translation factor eIF4B drives abnormal increases of laminin γ2 and MYC protein during neoplastic progression to squamous cell carcinoma.Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival.Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF.MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin γ2 expression in oral dysplasia and squamous cell carcinoma.Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineageMC1R is a potent regulator of PTEN after UV exposure in melanocytesA PGC1α-mediated transcriptional axis suppresses melanoma metastasis.Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.PGC-1 Coactivators: Shepherding the Mitochondrial Biogenesis of Tumors.Sequence motifs and free energies of selected natural and non-natural nucleosome positioning DNA sequences.Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant PotentialATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.PIK3CA mutant tumors depend on oxoglutarate dehydrogenase.BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.TGGA repeats impair nucleosome formation.Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors.ERRα Maintains Mitochondrial Oxidative Metabolism and Constitutes an Actionable Target in PGC1α-Elevated Melanomas.Small interfering RNA.Nucleosome structural features and intrinsic properties of the TATAAACGCC repeat sequenceIdentification and characterization of genomic nucleosome-positioning sequencesDNA sequence-dependent contributions of core histone tails to nucleosome stability: differential effects of acetylation and proteolytic tail removalPotent p53-independent tumor suppressor activity of ARF in melanoma-genesisIL1α antagonizes IL1β and promotes adaptive immune rejection of malignant tumors
P50
Q24297823-1ED47AF1-EA0D-4890-B5C3-2AC3EEE420C5Q24300451-6805405F-7012-4809-890C-81979EEA806AQ28204096-353E20AC-BC27-450B-B5E2-9102CB92614BQ28240846-E1799E0F-5B61-4732-AB68-7AE1437D6CF6Q29614282-3CE971EE-FA4F-47EB-8F82-446F7A5D4FF4Q33560698-07C467A4-A299-464F-824F-D092823E56F9Q33756912-BC2A45BA-BD61-4329-A861-20A6A3D4C265Q33909518-A9380A0B-F823-4D58-A70B-167CD3B68361Q34568270-19B037C2-D4E4-485A-90C1-02B6BD677441Q34601186-D22EC1E2-8AAF-4D69-AD39-1B0143C58763Q34781474-21671187-C6DB-4B9A-BCB4-CB485F89F553Q35036869-29034B49-A8B8-451F-8115-716254B76344Q35146535-C04CAB12-9BCF-485E-A91D-552D27A8A37DQ35470449-0672D918-F95C-4F05-AABF-AD6BD03B7093Q36044929-A135AEBA-231A-45C8-90A4-FDC264B449FAQ36376583-E14826BF-2CF7-4577-8139-FA068D365DF1Q37167249-A30C5112-C98F-44C0-8818-EEFF9A45B807Q37220171-E7FF8138-91CA-4999-83EF-5D45D7B83D09Q37510470-59CE1290-4F9E-4AAB-8B8D-3E52397F0D9FQ37545014-2D527955-19EC-458A-89F9-9F68A04CA9B8Q39193337-C29ACDDE-5680-4CC7-8BEB-9367692DA536Q39368524-C6F09451-5C5E-4DA3-8E28-CF586888D31EQ40813511-D72C9448-F79A-47D4-9C3F-47E2F090342CQ41780259-C20DFDDD-8361-4D92-90E9-0B28FFB2BC4BQ42321002-41AA63EB-2C0B-4C2F-A495-9E7820806B33Q42580090-C8D2299D-1867-4E54-A659-160909CB684EQ45252786-DC652BFB-1776-4573-BAA6-CB4A17F9D470Q47708985-C52E07BE-8237-4BEC-81D7-9F21E51BE534Q48123329-0AA5F5D7-D37A-478B-8B92-F184A6EAFC7BQ50952961-7373CB96-7178-406C-BC90-6466591C8B08Q54623165-C63ABAD9-5D1F-4956-9EA7-B8B438AF8A91Q73133695-46A70B1E-F075-4540-BCB2-7131A3C8E051Q73306445-FBC31FD1-4386-475B-8955-392F0729F09CQ73590493-2769912A-CE3C-4D70-BE6F-B7A072B20756Q81238883-BFA81632-E454-4212-AB62-82BD9F399342Q90244284-7BF7BECF-1A40-4028-AF7B-0F6CBCAC9CA2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hans R. Widlund
@ast
Hans R. Widlund
@en
Hans R. Widlund
@es
Hans R. Widlund
@nl
Hans R. Widlund
@sl
type
label
Hans R. Widlund
@ast
Hans R. Widlund
@en
Hans R. Widlund
@es
Hans R. Widlund
@nl
Hans R. Widlund
@sl
prefLabel
Hans R. Widlund
@ast
Hans R. Widlund
@en
Hans R. Widlund
@es
Hans R. Widlund
@nl
Hans R. Widlund
@sl
P106
P1153
6701774350
P21
P31
P496
0000-0002-7506-2447